Dr. Wei Hong 洪卫
Chief Physician
Department of Medical Oncology for Thoracic Tumors, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical and comprehensive treatment for lung cancer, esophageal cancer, mediastinal tumors, breast cancer, gastrointestinal tumors, testicular malignancies, prostate cancer, and malignant lymphoma.
Dr. Hong holds a medical doctorate and serves as Chief Physician in Medical Oncology. Research focuses on anti-angiogenesis and targeted therapy resistance in lung cancer, involving national and provincial projects. Dr. Hong received the Zhejiang Provincial Science and Technology Progress Award (Third Prize) and the Zhejiang Medical and Health Science and Technology Award (Second Prize). Publications include seven SCI papers.
Professional roles
- Standing Committee Member, Lung Tumor Professional Committee, China Medical Education Association
- Standing Committee Member, Targeted Therapy Branch, Chinese Geriatrics and Gerontology Society
- Member, Tumor Targeted Therapy Technology Branch, Chinese Society of Biomedical Engineering
- Editorial Board Member, Modern Doctor of China
Name order: in Chinese the family name comes first (Hong Wei). Papers usually list the name as Wei Hong or Hong W.
Selected publications
37 papers on PubMed matched by name and affiliation; 5 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Thorac Dis, 2024 (senior author): Efficacy and outcome analysis: monotherapy and combination therapy of S-1 for patients with advanced non-small cell lung cancer. PubMed 39552860
- J Cancer, 2021 (senior author): Genomic and clinical characteristics of MET exon14 alterations in a large cohort of Chinese cancer patients revealed distinct features and a novel resistance mechanism for crizotinib. PubMed 33403024
- Cancer Chemother Pharmacol, 2019 (senior author): Apatinib for chemotherapy-refractory extensive-stage SCLC: a retrospective study. PubMed 30937519
- Oncotarget, 2017 (senior author): Time to local recurrence as a predictor of survival in unrecetable gastric cancer patients after radical gastrectomy. PubMed 29179512
- Anticancer Res, 2016 (senior author): Human Serum Albumin Nanoparticles as a Novel Delivery System for Cabazitaxel. PubMed 27069142
- Zhongguo Fei Ai Za Zhi, 2014 (first author): [Advances on driver oncogenes of squamous cell lung cancer]. PubMed 24854563
- Zhongguo Fei Ai Za Zhi, 2014 (first author): [Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status]. PubMed 24758907
- J Zhejiang Univ Sci B, 2013 (first author): Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population. PubMed 23463763
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion